^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR G719S + EGFR L861Q

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. (PubMed, Ann Palliat Med)
    After 1 month of treatment, the patient achieved central nervous system (CNS) response, and at the time of this manuscript's submission, he had maintained stable disease (SD) for more than 1 year. To our knowledge, this study provides the first clinical evidence that the administration of osimertinib at 160 mg once daily can achieve an encouraging, durable response in an NSCLC patient with LM carrying EGFR G719S and L861Q.
    Clinical • Clinical protocol • Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719S • EGFR G719S + EGFR L861Q • EGFR L861R
    |
    Tagrisso (osimertinib)
    over3years
    Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series. (PubMed, Diagn Pathol)
    Our cases provide evidence for utility of NGS in facilitating diagnosis and treatment decisions.
    Clinical • Journal • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR L861Q • BRAF K601E • EGFR G719A • EGFR G719S • EGFR G719S + EGFR L861Q • BRAF V600_K601delinsE • BRAF K601
    |
    Conmana (icotinib)
    over4years
    Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients. (PubMed, Cancer Rep (Hoboken))
    Despite low sensitivity, combined DS, RFLP, and PCR-HRM was able to detect EGFR mutations in plasma cfDNA with high specificity. Moreover, TKI resistance exon 20 insertions mutation was detected as early as 3 months post TKI treatment.
    Clinical • Journal • HEOR
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR L858R + EGFR T790M • EGFR G719X • EGFR G719A • EGFR G719S • EGFR exon 18 mutation • EGFR G719C • EGFR L861Q + EGFR G719X • EGFR G719S + EGFR L861Q